#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	3534	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2044	299.9	0	.	n	.	0	C451T	SNP	451	451	C	618	618	T	351	T,G	198,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	3534	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2044	299.9	0	.	n	.	0	C1450T	SNP	1450	1450	C	1617	1617	T	362	T	206	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	3534	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2044	299.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1351	1351	C	402	C	234	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6328	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3350	319.9	0	.	n	.	0	T695C	SNP	695	695	T	890	890	C	412	C	237	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6328	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3350	319.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2166	2166	C	317	C	186	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6328	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3350	319.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2240	2240	A	326	A	195	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6328	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3350	319.9	1	SNP	n	C2597T	0	.	.	2597	2597	C	2792	2792	C	352	C	202	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	27	254	folP	852	852	100.0	folP.l15.c4.ctg.1	1307	33.9	1	SNP	p	R228S	0	.	.	682	684	CGC	926	928	CGC	35;35;35	C;G;C	22;21;22	folP.WHO_F_01537c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	531	636	gyrA	2751	2751	99.67	gyrA.l15.c4.ctg.1	3122	35.9	0	.	p	.	0	V19I	NONSYN	55	57	GTC	196	198	ATC	27;27;27	A;T;C	16;15;15	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	531	636	gyrA	2751	2751	99.67	gyrA.l15.c4.ctg.1	3122	35.9	0	.	p	.	0	M250I	NONSYN	748	750	ATG	889	891	ATA	32;32;32	A;T;A	22;20;20	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	531	636	gyrA	2751	2751	99.67	gyrA.l15.c4.ctg.1	3122	35.9	0	.	p	.	0	R771fs	FSHIFT	2311	2311	C	2452	2452	C	10	C	2	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	531	636	gyrA	2751	2751	99.67	gyrA.l15.c4.ctg.1	3122	35.9	1	SNP	p	S91F	0	.	.	271	273	TCC	412	414	TCC	47;47;47	T;C;C	29;28;28	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	531	636	gyrA	2751	2751	99.67	gyrA.l15.c4.ctg.1	3122	35.9	1	SNP	p	D95N	0	.	.	283	285	GAC	424	426	GAC	54;54;53	G;A;C	34;31;31	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	531	636	gyrA	2751	2751	99.67	gyrA.l15.c4.ctg.1	3122	35.9	1	SNP	p	D95G	0	.	.	283	285	GAC	424	426	GAC	54;54;53	G;A;C	34;31;31	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_F_01564	mtrR.WHO_F_01564	1	1	539	190	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1080	28.5	0	.	p	.	0	D79N	NONSYN	235	237	GAT	481	483	AAT	44;44;48	A;A;T	29;27;29	.	.
mtrR.WHO_F_01564	mtrR.WHO_F_01564	1	1	539	190	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1080	28.5	1	SNP	p	G45D	0	.	.	133	135	GGC	379	381	GGC	50;50;50	G;G;C	27;27;26	mtrR.WHO_F_01564:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	120	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	681	28.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	584	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2769	36.5	0	.	p	.	0	V421A	NONSYN	1261	1263	GTC	1461	1463	GCC	23;23;21	G;C;C	16;17;15	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	584	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2769	36.5	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1503	1505	GCA	26;26;26	G;C;A	18;18;16	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	584	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2769	36.5	1	SNP	p	D86N	0	.	.	256	258	GAC	456	458	GAC	47;47;47	G;A;C	28;26;26	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	584	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2769	36.5	1	SNP	p	S87W	0	.	.	259	261	AGT	459	461	AGT	47;51;51	A;G;T	28;31;31	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	584	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2769	36.5	1	SNP	p	S87R	0	.	.	259	261	AGT	459	461	AGT	47;51;51	A;G;T	28;31;31	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	584	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2769	36.5	1	SNP	p	S87I	0	.	.	259	261	AGT	459	461	AGT	47;51;51	A;G;T	28;31;31	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	584	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2769	36.5	1	SNP	p	S88P	0	.	.	262	264	TCC	462	464	TCC	51;51;51	T;C,A;C	32;31,1;30	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	574	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2586	38.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1439	1441	GGC	33;35;35	G,C;G;C	20,1;23;20	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.0.001	penA.0.001	1	1	27	614	penA	1746	1746	100.0	penA.l15.c17.ctg.1	2078	50.1	1	SNP	p	A311V	0	.	.	931	933	GCA	1126	1128	GCA	72;72;72	G;C;A	40;39;41	penA.0.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	27	614	penA	1746	1746	100.0	penA.l15.c17.ctg.1	2078	50.1	1	SNP	p	I312M	0	.	.	934	936	ATC	1129	1131	ATC	72;72;72	A;T;C	43;41;41	penA.0.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	27	614	penA	1746	1746	100.0	penA.l15.c17.ctg.1	2078	50.1	1	SNP	p	V316T	0	.	.	946	948	GTG	1141	1143	GTG	73;72;73	G;T;G	41;40;40	penA.0.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	27	614	penA	1746	1746	100.0	penA.l15.c17.ctg.1	2078	50.1	1	SNP	p	V316P	0	.	.	946	948	GTG	1141	1143	GTG	73;72;73	G;T;G	41;40;40	penA.0.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	27	614	penA	1746	1746	100.0	penA.l15.c17.ctg.1	2078	50.1	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1642	1644	ACC	34;34;32	A;C;C	21;21;19	penA.0.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	27	614	penA	1746	1746	100.0	penA.l15.c17.ctg.1	2078	50.1	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1696	1698	GCG	20;20;20	G;C,G;G	15;12,1;14	penA.0.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	27	614	penA	1746	1746	100.0	penA.l15.c17.ctg.1	2078	50.1	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1696	1698	GCG	20;20;20	G;C,G;G	15;12,1;14	penA.0.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	27	614	penA	1746	1746	100.0	penA.l15.c17.ctg.1	2078	50.1	1	SNP	p	G542S	0	.	.	1624	1626	GGC	1819	1821	GGC	17;17;17	G;G;C	12;12;13	penA.0.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	27	614	penA	1746	1746	100.0	penA.l15.c17.ctg.1	2078	50.1	1	SNP	p	G545S	0	.	.	1633	1635	GGC	1828	1830	GGC	18;18;17	G;G;C	13;13;11	penA.0.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	27	614	penA	1746	1746	100.0	penA.l15.c17.ctg.1	2078	50.1	1	SNP	p	P551S	0	.	.	1651	1653	CCG	1846	1848	CCG	17;16;16	C;C;G	10;9;9	penA.0.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	1124	ponA	2397	2397	99.87	ponA.l15.c17.ctg.1	2775	63.3	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1413	1415	CTG	37;37;36	C;T;G	19;21;21	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	316	porA	1146	1146	99.65	porA.l15.c17.ctg.1	1469	35.8	0	.	p	.	0	S22G	NONSYN	64	66	AGC	271	273	GGT	26;26;26	G;G;T	17;17;18	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	316	porA	1146	1146	99.65	porA.l15.c17.ctg.1	1469	35.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	453	453	C	26	C	17	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	374	porB1a	984	984	98.27	porB1a.l15.c17.ctg.1	1393	46.5	0	.	p	.	0	A29V	NONSYN	85	87	GCC	272	274	GTC	58;58;58	G;T;C	35;34;36	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	374	porB1a	984	984	98.27	porB1a.l15.c17.ctg.1	1393	46.5	0	.	p	.	0	T50A	NONSYN	148	150	ACT	335	337	GCT	52;52;52	G;C;T,G	29;30;29,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	374	porB1a	984	984	98.27	porB1a.l15.c17.ctg.1	1393	46.5	0	.	p	.	0	K88L	NONSYN	262	264	AAA	449	451	CTC	54;54;55	C;T;C	30;31;31	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	374	porB1a	984	984	98.27	porB1a.l15.c17.ctg.1	1393	46.5	0	.	p	.	0	S93N	NONSYN	277	279	AGC	464	466	AAC	47;47;47	A;A;C	25;24;28	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	374	porB1a	984	984	98.27	porB1a.l15.c17.ctg.1	1393	46.5	0	.	p	.	0	H111R	NONSYN	331	333	CAT	518	520	CGT	50;50;50	C,A;G;T	32,1;33;31	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	374	porB1a	984	984	98.27	porB1a.l15.c17.ctg.1	1393	46.5	0	.	p	.	0	N114S	NONSYN	340	342	AAC	527	529	AGC	47;47;46	A;G;C	32;29;29	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	374	porB1a	984	984	98.27	porB1a.l15.c17.ctg.1	1393	46.5	0	.	p	.	0	I115V	NONSYN	343	345	ATC	530	532	GTC	46;47;48	G;T;C	29;30;28	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	374	porB1a	984	984	98.27	porB1a.l15.c17.ctg.1	1393	46.5	0	.	p	.	0	D120G	NONSYN	358	360	GAC	545	547	GGC	47;47;47	G;G;C	30;27;29	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	374	porB1a	984	984	98.27	porB1a.l15.c17.ctg.1	1393	46.5	0	.	p	.	0	R143H	NONSYN	427	429	CGC	614	616	CAC	47;47;47	C;A,C;C	25;25,1;27	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	374	porB1a	984	984	98.27	porB1a.l15.c17.ctg.1	1393	46.5	0	.	p	.	0	Y201F	NONSYN	601	603	TAC	788	790	TTC	64;64;65	T;T;C	37;36;37	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	374	porB1a	984	984	98.27	porB1a.l15.c17.ctg.1	1393	46.5	0	.	p	.	0	T202M	NONSYN	604	606	ACG	791	793	ATG	66;66;64	A;T;G	37;36;35	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	374	porB1a	984	984	98.27	porB1a.l15.c17.ctg.1	1393	46.5	0	.	p	.	0	S236R	NONSYN	706	708	AGC	893	895	CGC	74;74;74	C;G;C	42;42;41	.	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	1700	rpoB	4179	4179	99.93	rpoB.l15.c4.ctg.1	4642	63.3	1	SNP	p	H553N	0	.	.	1657	1659	CAT	1810	1812	CAT	82;82;82	C;A;T	49;49;48	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_F_02142c	rpsJ.WHO_F_02142c	1	1	27	196	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	973	39.2	1	SNP	p	V57M	0	.	.	169	171	GTG	522	524	GTG	61;61;65	G;T;G	37;40;42	rpsJ.WHO_F_02142c:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
